^
    3ms
    A Study to Evaluate the Efficacy and Safety of HS-10382 in Patients with Newly Diagnosed ChronicPhase Chronic Myeloid Leukemia. (ChiCTR2400088230)
    P=N/A, N=20, Recruiting, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine; Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
    New trial
    |
    TERN-701
    5ms
    Study of HS-10382 Combination in Patients With Chronic Myeloid Leukemia (CML) (clinicaltrials.gov)
    P1, N=100, Not yet recruiting, Jiangsu Hansoh Pharmaceutical Co., Ltd.
    New P1 trial • Combination therapy
    |
    Hansoh Xinfu (flumatinib) • TERN-701
    1year
    CARDINAL- A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (clinicaltrials.gov)
    P1, N=80, Not yet recruiting, Terns, Inc.
    New P1 trial
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
    |
    TERN-701
    over1year
    The Novel BCR::ABL1 Allosteric Inhibitor HS‑10382/TERN‑701 is Potent Against Mutations Resistant to Active Site Tyrosine Kinase Inhibitors (TKIs) and Acts Synergistically With TKIs in BCR::ABL1+ Cancer Cell Lines (SOHO 2023)
    TERN-701/HS-10382 is a potent and selective allosteric inhibitor of BCR::ABL1 in cell- free and cell-based assays and screens, with comparable potency and synergy profiles to that of asciminib while potentially being more selective. TERN-701/HS-10382 retains activity against the T315I gatekeeper mutation, which confers resistance to all approved active site TKIs except for ponatinib, which has known safety liabilities. These data support the continued development of TERN-701/ HS-10382 for the treatment of CML.
    Preclinical
    |
    ABL1 (ABL proto-oncogene 1)
    |
    ABL1 T315I
    |
    Iclusig (ponatinib) • Scemblix (asciminib) • TERN-701
    over1year
    A PHASE 1 MULTICENTER OPEN-LABEL DOSE-ESCALATION AND DOSE- EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, EFFICACY OF HS-10382 (TERN-70) IN CHRONIC MYELOID LEUKEMIA PATIENTS (EHA 2023)
    This study is ongoing (enrollment underway for Part 1, dose 3 as of February 2023) with 7 participating study sites in China. Clinical trial information: NCT05367700. Phase I, Chronic myeloid leukemia, BCR-ABL
    Clinical • P1 data • PK/PD data
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
    |
    ABL1 T315I
    |
    TERN-701
    almost2years
    A Study of HS-10382 in Patients With Chronic Myeloid Leukemia. (clinicaltrials.gov)
    P1, N=108, Recruiting, Jiangsu Hansoh Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting | Trial completion date: Sep 2024 --> Sep 2026 | Trial primary completion date: Dec 2022 --> Dec 2024
    Enrollment open • Trial completion date • Trial primary completion date
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
    |
    BCR-ABL1 fusion
    |
    TERN-701
    over2years
    A Study of HS-10382 in Patients With Chronic Myeloid Leukemia. (clinicaltrials.gov)
    P1, N=108, Not yet recruiting, Jiangsu Hansoh Pharmaceutical Co., Ltd.
    New P1 trial
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
    |
    BCR-ABL1 fusion
    |
    TERN-701